Full Press Release Details
ZIOPHARM Issues Statement Regarding Misleading
NEW YORK, NY - October 19, 2012
- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today issued the following statement regarding a blog entry posted by Richard
Pearson, Contributor, on Forbes.com:
"The statements made in Mr. Pearson's
blog entry are misleading and wrong and, given his disclosed investment position, we call into question the entire credibility
of this piece. The Form 483 was issued directly to the independent investigator, not to ZIOPHARM, and had nothing to do with any
outcome measures of the Phase 2 PICASSO study. All regulatory matters raised in Mr. Pearson's blog entry were resolved by
the investigator in full in 2010, and had no impact on the Company's transition from Phase 2 to Phase 3. Further, the Company
has no issues with drug stability. We stand by the clinical data generated at this investigator's site. Consistent with best
practices, all data from ZIOPHARM's Phase 2 PICASSO study at this site were reviewed by an independent, former FDA good clinical
practice (GCP) auditor, and the auditor concluded that the study site's violations had no impact on the PICASSO study or
the quality of data."
About ZIOPHARM Oncology, Inc.:
is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. ZIOPHARM's operations
are located in Boston, MA, and New York City. Further information about ZIOPHARM may be found at www.ziopharm.com.
ZIOPHARM Oncology, Inc.
David Schull or Lena Evans